Ilya Pharma AB

Developing the next-generation
biological drugs for treating wounds
in skin and mucosa

In press

2018-04-11

  Our research applauded in Cell Host and Microbe

”Time heals all wounds...... but wounds heal faster with Lactobacillus” is the title of a commentary to our preclinical results (Vågesjö et al. 2018 PNAS) published by the very prestigious journal Cell-Host and Microbe. The authors summarizes our demonstration of a feasible and translatable therapeutic approach acceleration of wound healing with topical application of CXCL12-producing Lactobacilli and applauds the approach and the first steps in the drug development program. Chronic non-healing wounds represent a significant clinical problem and cost the healthcare system $19 billion annually. Our developed drug candidate being an advanced therapeutic medicinal product, is in the article referred to as a ”promising technology for the unsolved problem of delayed cutaneous wound healing”.


Next

Ilya Pharma

Ilya Pharma, an innovative Swedish pharmaceutical company, develops drug candidates for PoC in clinical phase I and II from its technology platform of lactic acid bacteria expressing different human therapeutic proteins.

 

Next

Technology

Human therapeutic proteins are delivered on site in wounds by living lactic acid bacteria acting like small bioreactors. This is a very cost-effective way to deliver biological drugs.

We have a freeze-dried formulation with good stability. The lactic acid bacteria are revived immediately prior use by addition of a small volume of water.

Next

Science

The innovation stems from world-leading medical research in immunophysiology and microbiology at Uppsala University and the Swedish University of Agricultural Sciences. The treatments target the function of tissue-resident immune cells and the mechanism of accelerated healing is defined by us and published in high impact scientific journals.

Next

Unmet clinical need

The unmet clinical need targeted by Ilya Pharma is healing both acute and chronic wounds,  especially problematic for people with diabetes. Indications in the gastrointestinal tract such as irritable bowel disease are also being explored.

There is much room for improvement in wound care and the innovative technology of Ilya Pharma offers a more efficient and very cost effective treatment compared to treatment with conventional biological drugs, expected to enter the wound care market.

Next

Investor relations

Ilya Pharma is financed by a mix of research- and innovation grants and private funding. A $3M H2020 grant (!) covers activities in 2018. Suitable investors and partners in the field of Pharma and biologics are invited to contact us.

Contact

Next

Core team

 

Evelina Vågesjö, CEO

Co-founder, PhD in physiology. Developed methods to steer immune cell function to accelerate healing and blood flow regulation in the lab of Professor Mia Phillipson. Also delineated the mechanism of action during this time. BSc in Management Accounting and will complete an MBA during 2017.

Mia Phillipson, CSO

Co-founder, facilitator and Professor in Physiology at Uppsala University. Internationally recognized expert in physiology and immunology. Multiple discoveries in Professor Phillipson’s lab have led to clinical initiatives.

Stefan Roos, CTO

Co-founder and Ass. Professor in Microbiology at the Swedish University of Agricultural Sciences. Has long research experience in microbiology and bacteria-host interactions. Special expertise in lactic acid bacteria biology, technology transfer and the commercialization of probiotic innovations.

Göran Beijer, Board member

Co-founder with long experience from leading positions in the biotechnology and life-science industries focusing on business development. Formerly CEO ONCOlog AB and NOLabs AB. Has held executive positions at Tamro, Astra Zeneca and Pharmacia. 

Ingemar Kihlström, Chairman of the Board

Extensive experience in finance and drug development at multiple firms including Astra Zeneca and Pharmacia. PhD in physiology/toxicology from Uppsala University. Experience from serving at the board of >30 companies often as chairman. Co-founder of life science companies and managed several licensing deals and IPOs in the industry. 

 

 

Next

Contact Us

info@ilyapharma.se

Ilya Pharma AB, Uppsala, Sweden

Evelina Vågesjö, CEO
+46 (0)70 636 64 94